Dapagliflozin

Where the papers sit

24 papers from the last 6 months study dapagliflozin directly · updated from PubMed 12 Oct 2026

• SGLT2 Renoprotection in Diabetes

  Renal protection is being linked to more than glucose lowering, with SGLT2 inhibition altering metabolic, vascular, inflammatory and senescence markers in diabetic kidneys. Mechanistic studies point to SLC5A2-SRC-ERK/STAT3, CTRP1-mediated glucotoxic stress, AGE-RAGE-IGFBP2-FBN1 and Nrf2/HO-1 pathways. Work is moving toward testing preservation of renal structure and function in kidney transplant recipients, while youth with type 1 diabetes provide early biomarker evidence. Cerebral ischemia and diabetic lens findings broaden the proposed organ-protective effects but remain preclinical.

  8 papers · 33.3%

• Heart Failure Cardiovascular Outcomes

  Heart failure care is shifting from isolated glycaemic treatment toward cardiovascular-risk reduction and real-world deployment of SGLT2 inhibitors. Dapagliflozin and empagliflozin are being compared for major adverse cardiovascular events, while uptake after guideline expansion and healthcare costs test implementation. Preclinical work links dapagliflozin to less cardiac fibrosis, steatosis and diastolic dysfunction, including HIV-associated disease. Evidence in transthyretin cardiac amyloidosis remains exploratory, based on an n-of-1 pilot rather than established outcome benefit.

  6 papers · 25%

• Type 2 Diabetes Treatment

  Type 2 diabetes treatment is moving toward combination and head-to-head strategies rather than dapagliflozin alone. Orforglipron, semaglutide plus dapagliflozin, empagliflozin and DPP-4 inhibitors are assessed against HbA1c, postprandial glucose, adverse events and clinical outcomes. Dapagliflozin is also being tested for hepatic steatosis and fibrosis in metabolic dysfunction-associated steatotic liver disease. A spectrofluorimetric assay paper addresses formulation measurement, not therapeutic benefit, and sits at the edge of this clinical theme.

  5 papers · 20.8%

• Others — Pleiotropic Organ Effects

  Renal, cardiac, skeletal and ocular effects are being explored in separate dapagliflozin applications, with no single clinical question tying them together. Kidney studies test klotho, mitophagy, apoptosis, fibrosis and liraglutide combination therapy in diabetic injury. Other reports address Cx43 in diabetic cardiomyopathy, bone effects in dialysis, and polymeric nanomicelles for glaucoma delivery. The work is exploratory and preclinical or small-scale, so it does not establish a common therapeutic direction.

  5 papers · 20.8%